Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.69 SEK | -2.90% |
|
-27.20% | +2.15% |
06-20 | Transcript : Egetis Therapeutics AB - Special Call | |
06-19 | Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency | CI |
End-of-day quotes
Sector Bio Therapeutic Drugs
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
163M | - | |||||
122B | ||||||
116B | ||||||
27.03B | - | |||||
20.36B | - | |||||
15.91B | - |